ASCO 2024: A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC)
Used in the poster: YH003 Poster Highlights: YH003 + Toripalimab with/without chemotherapy, as 1L or 2L+ treatment in patients with u/m PDAC have promising anti-tumor…
Read more
IO Summit Europe 2024: Fully Human Conditional Agonist 4-1BB×CD40 Bispecific Antibody Exhibits Potent In Vitro and In Vivo Efficacy
Used in the poster: BsAb Discovery Platform Summary: 4-1BB and CD40 agonists are promising candidates for cancer immunotherapy but have had limited success…
Read more
Festival of Biologics 2024: Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)
Used in the poster: Bispecific ADC Platform Summary: Biocytogen's antibody discovery team has generated a library of antibodies targeting approximately 200 tumor-associated antigens…
Read more
AACR 2024: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies
Used in the poster: TCR-Mimic Antibody Platform Summary: Novel antibodies highly specific to KRAS mutations (G12V and G12D) presented by human leukocyte antigen (HLA) were…
Read more
AACR 2024: Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo
Used in the poster: B-hIL5/hIL5RA mice Summary: IL-5/IL-5R signaling is crucial for eosinophil function and has therapeutic implications for inflammatory diseases like asthma. We developed…
Read more
AACR 2024: A novel humanized NKP46 mouse model to support xenograft studies evaluating NK cell-based cancer immunotherapies
Used in the poster: B-hNKP46 mice Summary: The NKP46 receptor is vital for NK cell recognition and activation against tumors, making it a target for…
Read more
AACR 2024: Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines
Used in the poster: B-HLA-A11.1 mice, B-HLA-A24.2 mice Summary: The HLA class I major histocompatibility complex is crucial for immune surveillance and is being explored…
Read more
AACR 2024: Generation of a novel severely immunodeficient Sprague Dawley rat model for xenograft studies
Used in the poster: B-SDG rats Summary: Rag2 is essential for T and B cell development, while Il2rg is crucial for various immune cell functions.…
Read more
AACR 2024: A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC
Used in the poster: B-hCD16A mice(CB-17 SCID) Summary: Antibody-dependent cellular cytotoxicity (ADCC) is crucial for cancer immunotherapy, primarily mediated by the CD16A receptor on human…
Read more
AACR 2024: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts
Used in the poster: Bispecific ADC Platform Summary: A bispecific antibody-drug conjugate (bsADC), BCG033, targeting both TROP2 and PTK7, demonstrated promising preclinical efficacy in triple-negative…
Read more
AACR 2024: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity
Used in the poster: Bispecific ADC Platform Summary: A novel bispecific antibody-drug conjugate (ADC), BCG016, targeting both 5T4 and MUC1-C antigens, was developed for solid…
Read more
AACR 2024: A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation
Used in the poster: Bispecific ADC Platform Summary: EGFR and HER3 are prevalent in epithelial tumors, particularly in lung cancer where EGFR often exhibits mutations…
Read more